Subscribe
rudmer-zwerver-shutterstock-com
Rudmer Zwerver / Shutterstock.com
3 February 2016Biotechnology

English High Court revokes Regeneron’s transgenic mice patents

The English High Court has revoked two European patents owned by Regeneron Pharmaceuticals covering transgenic mice.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
English appeals court overturns Regeneron transgenic mice decision
29 March 2018   The English Court of Appeal has reversed a finding that two of Regeneron’s European patents covering transgenic mice were insufficient.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Biotechnology
English appeals court overturns Regeneron transgenic mice decision
29 March 2018   The English Court of Appeal has reversed a finding that two of Regeneron’s European patents covering transgenic mice were insufficient.

More on this story

Biotechnology
English appeals court overturns Regeneron transgenic mice decision
29 March 2018   The English Court of Appeal has reversed a finding that two of Regeneron’s European patents covering transgenic mice were insufficient.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims